Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received a medical device license from China’s National Medical Products Administration (NMPA) for its innovative MemoSORB biodegradable atrial septal defect occluder.
This cutting-edge device offers significant advantages over traditional nitinol occluders by markedly reducing inflammatory responses, alleviating fibrosis, and promoting endothelialization through its unique biodegradable depolymerization process. Notably, once the occluder degrades, it facilitates the natural reconstruction of the atrial septum, preserving tissue elasticity and ensuring that future interventional procedures through the atrial septum remain unaffected. This design is expected to enhance the long-term health outcomes for patients.- Flcube.com
